Literature DB >> 15593459

Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomach.

Yoshinari Mochizuki1, Yasuhiro Kodera, Seiji Ito, Yoshitaka Yamamura, Yukihide Kanemitsu, Yasuhiro Shimizu, Takashi Hirai, Kenzo Yasui, Ken-ichi Inada, Tomoyuki Kato.   

Abstract

The current definitive treatment for gastrointestinal stromal tumor (GIST) of the stomach is complete resection. GIST has a highly variable clinical course, and recurrent disease sometimes develops despite curative treatment. Although several known risk factors for recurrence exist, adequate treatment strategies are lacking. This study evaluated factors associated with relapse after curative treatment. Sixty patients with gastric GIST were identified from a hospital disease registry database. Clinicopathologic characteristics of these patients were reviewed and the Cox proportional hazards regression analysis was used to identify recurrent risk factors. With a median follow-up of 60 months (range 5-286 months), recurrence occurred in eight (13%) patients, three of whom underwent resection of the recurrent disease and are alive to date. Univariate analysis demonstrated that invasion of the adjacent organs (p = 0.0005), tumor size (p = 0.0046), and expression of proliferative markers [MIB-1 proliferative index (PI) > or = 10%] (p = 0.0001) were significant risk factors for recurrence. Multivariate analysis with these three factors as variables revealed that only MIB-1 PI was a significant independent risk factor for recurrence (p = 0.0051). In conclusion, surgical resection may be indicated whenever a recurrent GIST is considered resectable. A high MIB-1 PI was identified as an independent indicator of risk for recurrent disease following curative surgery.

Entities:  

Mesh:

Year:  2004        PMID: 15593459     DOI: 10.1007/s00268-004-7418-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  33 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung.

Authors:  L M Demarchi; M M Reis; S A Palomino; C Farhat; T Y Takagaki; R Beyruti; P H Saldiva; V L Capelozzi
Journal:  Mod Pathol       Date:  2000-05       Impact factor: 7.842

4.  The effect of surgery and grade on outcome of gastrointestinal stromal tumors.

Authors:  J P Pierie; U Choudry; A Muzikansky; B Y Yeap; W W Souba; M J Ott
Journal:  Arch Surg       Date:  2001-04

Review 5.  Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management.

Authors:  I Pidhorecky; R T Cheney; W G Kraybill; J F Gibbs
Journal:  Ann Surg Oncol       Date:  2000-10       Impact factor: 5.344

Review 6.  Gastrointestinal stromal tumors.

Authors:  S Suster
Journal:  Semin Diagn Pathol       Date:  1996-11       Impact factor: 3.464

7.  Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.

Authors:  Peter C Wu; Alex Langerman; Christopher W Ryan; John Hart; Susan Swiger; Mitchell C Posner
Journal:  Surgery       Date:  2003-10       Impact factor: 3.982

8.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

9.  Elevated (> or = 10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: a study of 35 cases.

Authors:  Claire Toquet; Jean Claude Le Néel; Louis Guillou; Karine Renaudin; Antoine Hamy; Marie-Françoise Heymann; Sophie Simon-Valla; Joël Le Borgne; Christine Maugard; Maryse Fiche
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

10.  Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade.

Authors:  Tadashi Hasegawa; Yoshihiro Matsuno; Tadakazu Shimoda; Setsuo Hirohashi
Journal:  Hum Pathol       Date:  2002-06       Impact factor: 3.466

View more
  13 in total

Review 1.  Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach.

Authors:  Robert J Coffey; Mary Kay Washington; Christopher L Corless; Michael C Heinrich
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Laparoscopic wedge resection for gastrointestinal stromal tumors of the stomach: initial experience.

Authors:  Yoshinari Mochizuki; Yasuhiro Kodera; Michitaka Fujiwara; Seiji Ito; Yoshitaka Yamamura; Akira Sawaki; Kenji Yamao; Tomoyuki Kato
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

3.  Surgical margin status and prognosis of gastrointestinal stromal tumor.

Authors:  António M Gouveia; Amadeu P Pimenta; Ana F Capelinha; Dionísio de la Cruz; Paula Silva; José M Lopes
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

4.  Different sites and prognoses of gastrointestinal stromal tumors of the stomach: report of 187 cases.

Authors:  Hai Huang; Yan-Xue Liu; Zhong-Li Zhan; Han Liang; Pu Wang; Xiu-Bao Ren
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

5.  Abdominal wound metastasis after laparoscopic surgery of gastrointestinal stromal tumor.

Authors:  Min Dae Kim; Dae Hwan Kang; Jong Hwan Park; Jin Ho Lee; Cheol Woong Choi; Do Hoon Kim; Hyung Wook Kim; Gwang Ha Kim
Journal:  Gut Liver       Date:  2010-06-16       Impact factor: 4.519

6.  Diagnosis and surgical treatment of esophageal gastrointestinal stromal tumors.

Authors:  Fang-Biao Zhang; Hong-Can Shi; Yu-Sheng Shu; Wei-Ping Shi; Shi-Chun Lu; Xiang-Yan Zhang; Shao-Song Tu
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

7.  Coincidental Detection of Gastrointestinal Stromal Tumors During Laparoscopic Bariatric Procedures-Data and Treatment Strategy of a German Reference Center.

Authors:  Orestis Lyros; Yusef Moulla; Matthias Mehdorn; Katrin Schierle; Robert Sucher; Arne Dietrich
Journal:  Obes Surg       Date:  2019-06       Impact factor: 4.129

8.  The outcome of gastrointestinal stromal tumors (GISTs) after a surgical resection in our institute.

Authors:  Kazunori Tsukuda; Ryuji Hirai; Takayoshi Miyake; Shoji Takagi; Eiji Ikeda; Tadayoshi Kunitomo; Hisashi Tsuji
Journal:  Surg Today       Date:  2007-10-25       Impact factor: 2.549

9.  Potential indicators predict progress after surgical resection of gastrointestinal stromal tumors.

Authors:  Qinggang Hu; Shanglong Liu; Jianwei Jiang; Chen Zhang; Xiaowei Liu; Qichang Zheng
Journal:  Front Med       Date:  2012-07-14       Impact factor: 4.592

10.  Recurring gastrointestinal stromal tumor with splenic metastasis.

Authors:  Ho Gun Kim; Seong Yeob Ryu; Jae Kyoon Joo; Hyo Kang; Jae Hyuk Lee; Dong Yi Kim
Journal:  J Korean Surg Soc       Date:  2011-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.